var data={"title":"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Bruce R Korf, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Marc C Patterson, MD, FRACP</a></dd><dd><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Helen V Firth, DM, FRCP, DCH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Elizabeth TePas, MD, MS</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 05, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H20885983\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are three major clinically and genetically distinct forms of neurofibromatosis: neurofibromatosis types 1 and 2 (NF1 and NF2) and schwannomatosis. NF1, also known as von Recklinghausen disease, is the most common type. The hallmarks of NF1 are the multiple caf&eacute;-au-lait macules and neurofibromas. The condition is called segmental NF1 when clinical features are limited to one area of the body.</p><p>The pathogenesis, clinical features, and diagnosis of NF1 are reviewed here. Management and prognosis are discussed separately (see <a href=\"topic.htm?path=neurofibromatosis-type-1-nf1-management-and-prognosis\" class=\"medical medical_review\">&quot;Neurofibromatosis type 1 (NF1): Management and prognosis&quot;</a>). The other two forms of neurofibromatosis, NF2 and schwannomatosis, are also discussed in detail separately. (See <a href=\"topic.htm?path=neurofibromatosis-type-2\" class=\"medical medical_review\">&quot;Neurofibromatosis type 2&quot;</a> and <a href=\"topic.htm?path=schwannomatosis\" class=\"medical medical_review\">&quot;Schwannomatosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H20885991\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>NF1 is an autosomal dominant genetic disorder with an incidence of approximately 1 in 2600 to 3000 individuals [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Approximately one-half of the cases are familial (inherited). The remainder are the result of de novo (sporadic) mutations [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/2\" class=\"abstract_t\">2</a>]. The de novo mutations occur primarily in paternally derived chromosomes, and the likelihood of de novo NF1 increases with advanced paternal age [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/3\" class=\"abstract_t\">3</a>]. The incidence of segmental NF1 is estimated at 1 in 36,000 to 40,000 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/4\" class=\"abstract_t\">4</a>].</p><p class=\"headingAnchor\" id=\"H20885999\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>NF1 is due to mutations in the <em>NF1</em> gene, located at chromosome 17q11.2 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/5,6\" class=\"abstract_t\">5,6</a>]. Neurofibromin, the protein product encoded by the gene, is expressed in many tissues, including brain, kidney, spleen, and thymus [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/7\" class=\"abstract_t\">7</a>]. It belongs to a family of guanosine triphosphate hydrolase (GTPase)-activating proteins (GAPs) that stimulate intrinsic GTPase activity in the ras p21 family (21 kD rat sarcoma viral oncogene homologs) [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/8-10\" class=\"abstract_t\">8-10</a>]. Ras activates a number of signaling pathways that includes the stem cell factor <span class=\"nowrap\">(SCF)/c-kit</span> signaling, mechanistic target of rapamycin (mTOR), and mitogen-activated protein kinase (MAPK) pathways.</p><p>Mutations in the <em>NF1</em> gene result in loss of production or reduced function of protein, causing the wide spectrum of clinical findings, including NF1-associated tumors [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/7\" class=\"abstract_t\">7</a>]. Penetrance, or the likelihood that the individual carrying the mutation will manifest the disorder, is complete. NF1 is highly variable in its expression, however (ie, the severity of and specific manifestations of the disorder vary among affected individuals within the same family and from one family to another) [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/11\" class=\"abstract_t\">11</a>]. Somatic mutation or loss of heterozygosity at the <em>NF1</em> locus, in combination with a germline NF1 mutation, leads to complete loss of neurofibromin expression that is seen in NF1 lesions such as pseudoarthrosis [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/12\" class=\"abstract_t\">12</a>] and neurofibromas [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/13\" class=\"abstract_t\">13</a>]. <em>NF1</em> therefore functions as a tumor suppressor gene.</p><p>Several thousand distinct pathogenic <em>NF1</em> mutations have been identified in affected individuals. Few obvious genotype-phenotype correlations have been demonstrated in patients with small mutations (&lt;20 base pairs) of the <em>NF1</em> gene. The c.2970-2972 delAAT (p.M990del) mutation is associated with a very mild phenotype in the majority of cases [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/14\" class=\"abstract_t\">14</a>]. These patients do not develop neurofibromas, unlike most other mutations that truncate or prevent neurofibromin formation. Patients with various amino acid substitutions at codon 1809, which normally encodes an arginine, also tend to lack neurofibromas but may have caf&eacute;-au-lait spots, intellectual disability, and Noonan syndrome-like features [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/15,16\" class=\"abstract_t\">15,16</a>]. Patients with a phenotype referred to as &quot;spinal NF,&quot; who have internal and paraspinal neurofibromas but few cutaneous tumors, tend to have splicing or missense mutations [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/17\" class=\"abstract_t\">17</a>].</p><p>Approximately 1 to 5 percent of patients with NF1 have large deletions that encompass 1.4 to 1.5 Mb of DNA and include the entire <em>NF1</em> gene [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/7,18,19\" class=\"abstract_t\">7,18,19</a>]. Such patients have a higher incidence of intellectual disability, developmental delay, some dysmorphic facial features, earlier appearance of cutaneous neurofibromas, and connective tissue abnormalities [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/20,21\" class=\"abstract_t\">20,21</a>]. They also appear to have an increased risk of malignant peripheral nerve sheath tumors (MPNSTs) [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/22,23\" class=\"abstract_t\">22,23</a>], which is in part due to deletion of the <em>SUZ12</em> gene that is contiguous to <em>NF1</em> [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/24,25\" class=\"abstract_t\">24,25</a>].</p><p>Segmental NF1 is caused by somatic mosaicism due to a postzygotic mutation in the <em>NF1</em> gene [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/26\" class=\"abstract_t\">26</a>]. This results in some cells having two normal <em>NF1</em> genes and other cells containing a mutation in one copy of the <em>NF1</em> gene. In most cases, patients with segmental NF1 have no affected relatives. When an adult with localized NF1 who has mosaicism within both somatic and gonadal tissues transmits the mutation to a child, this offspring will carry the <em>NF1 </em>mutation in all of <span class=\"nowrap\">his/her</span> cells and will not have segmental disease [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/4,27\" class=\"abstract_t\">4,27</a>]. Rare individuals have been described who have only germline mosaicism without apparent somatic features [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/28-31\" class=\"abstract_t\">28-31</a>].</p><p class=\"headingAnchor\" id=\"H20886007\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The typical order of appearance of clinical manifestations is caf&eacute;-au-lait macules, axillary <span class=\"nowrap\">and/or</span> inguinal freckling, Lisch nodules (iris hamartomas), and neurofibromas [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/32\" class=\"abstract_t\">32</a>]. Osseous dysplasias, if present, usually appear during the patient's first year after birth, and symptomatic optic pathway glioma (OPG) usually occurs by the time the patient is three years of age (<a href=\"image.htm?imageKey=PEDS%2F53064\" class=\"graphic graphic_table graphicRef53064 \">table 1</a>). Other tumors and neurologic complications typically begin to appear after the first year of life. Hypertension may occur in childhood. Malignant transformation of tumors may also occur in childhood but more often occurs in adolescence and adulthood.</p><p class=\"headingAnchor\" id=\"H19620235\"><span class=\"h2\">Caf&eacute;-au-lait macules</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Caf&eacute;-au-lait macules are flat, uniformly hyperpigmented macules that appear during the first year after birth and usually increase in number during early childhood (<a href=\"image.htm?imageKey=ALLRG%2F96125\" class=\"graphic graphic_picture graphicRef96125 \">picture 1</a>). The number of caf&eacute;-au-lait macules then stabilizes over time. Up to 15 percent of the normal population has one to three caf&eacute;-au-lait macules. However, the presence of six or more caf&eacute;-au-lait macules is highly suggestive of NF1 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/33,34\" class=\"abstract_t\">33,34</a>]. One retrospective study used age and <span class=\"nowrap\">number/type</span> of caf&eacute;-au-lait macules at the time of presentation to determine risk of having NF1 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/35\" class=\"abstract_t\">35</a>]. Younger age at presentation (&le;29 months) and presence of &ge;6 caf&eacute;-au-lait macules was associated with a high risk of having NF1 (80.4 percent, 95% CI 74.6-86.2 percent) compared with age &gt;29 months and fewer than six caf&eacute;-au-lait macules or at least one atypical caf&eacute;-au-lait macule (0.9 percent, 95% CI 0-2.6 percent). (See <a href=\"topic.htm?path=benign-pigmented-skin-lesions-other-than-melanocytic-nevi-moles#H8\" class=\"medical medical_review\">&quot;Benign pigmented skin lesions other than melanocytic nevi (moles)&quot;, section on 'Caf&eacute;-au-lait macule'</a> and <a href=\"#H20886015\" class=\"local\">'Diagnosis'</a> below.)</p><p>Approximately 95 percent of adults with NF1 have caf&eacute;-au-lait macules (<a href=\"image.htm?imageKey=PEDS%2F69606\" class=\"graphic graphic_picture graphicRef69606 \">picture 2</a>), but they tend to fade later in life and may be difficult to distinguish in older individuals. A Wood's lamp often is useful to visualize these macules when they are not readily discernible by gross inspection [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/36\" class=\"abstract_t\">36</a>], although the diagnostic criteria specify examination in ordinary room lighting. (See <a href=\"topic.htm?path=office-based-dermatologic-diagnostic-procedures#H4044225\" class=\"medical medical_review\">&quot;Office-based dermatologic diagnostic procedures&quot;, section on 'Wood's lamp examination (black light)'</a>.)</p><p class=\"headingAnchor\" id=\"H19620716\"><span class=\"h2\">Freckling</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Freckling is a diagnostic criterion distinct from caf&eacute;-au-lait macules. The freckles are smaller in size than caf&eacute;-au-lait macules, appear later, and usually occur in clusters in skin folds rather than randomly (<a href=\"image.htm?imageKey=ALLRG%2F96124\" class=\"graphic graphic_picture graphicRef96124 \">picture 3</a>).</p><p>Freckling occurs mostly in regions of skin apposition, especially the axillary and inguinal areas. Freckling usually is not apparent at birth but often appears by age three to five years, typically first in the inguinal region [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/33\" class=\"abstract_t\">33</a>]. Freckling may also occur in other intertriginous areas, such as the neckline or inframammary areas in women. In some individuals, freckling may occur elsewhere on the body and may be diffuse. One or two small freckles or the presence of a caf&eacute;-au-lait macule in a skin fold does not fulfill the diagnostic criterion for skin fold freckling.</p><p class=\"headingAnchor\" id=\"H19621894\"><span class=\"h2\">Lisch nodules</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lisch nodules are raised, tan-colored hamartomas of the iris and represent a specific finding for NF1. These do not affect vision in any manner.</p><p>Lisch nodules are useful both in establishing a diagnosis of NF1 in a child and determining whether a parent is affected. These lesions are detected in fewer than 10 percent of affected children younger than six years of age but are seen in greater than 90 percent of adults. They may be seen with a direct ophthalmoscope, if the nodules are large or numerous and the iris is light (<a href=\"image.htm?imageKey=PEDS%2F74414\" class=\"graphic graphic_picture graphicRef74414 \">picture 4</a>), but are best seen thorough slit-lamp examination by an ophthalmologist to detect the lesions and to distinguish them from iris nevi [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/37\" class=\"abstract_t\">37</a>].</p><p class=\"headingAnchor\" id=\"H1814439\"><span class=\"h2\">Tumors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with NF1 develop both benign and malignant tumors at increased frequency throughout life [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/38,39\" class=\"abstract_t\">38,39</a>]. Neurofibromas are the most common type of benign tumor that develops in patients with NF1. OPGs are the predominant type of intracranial neoplasms, but other central nervous system (CNS) and non-CNS tumors can occur.</p><p>The overall risk of malignancy in NF1 is increased in patients under 50 years of age, with a rate that is approximately 2.5- to 4-fold higher than that of the general population [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/40-42\" class=\"abstract_t\">40-42</a>].</p><p class=\"headingAnchor\" id=\"H19620723\"><span class=\"h3\">Peripheral neurofibromas</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Neurofibromas are benign peripheral nerve sheath tumors that are comprised of a mixture of Schwann cells, fibroblasts, perineurial cells, and mast cells [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/43\" class=\"abstract_t\">43</a>]. The Schwann cells may be abnormal in NF1 patients, and they can have angiogenic and invasive properties in plexiform neurofibromas (<a href=\"image.htm?imageKey=ALLRG%2F55032\" class=\"graphic graphic_picture graphicRef55032 \">picture 5</a>) [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/44\" class=\"abstract_t\">44</a>]. It is in the Schwann cells where loss of both <em>NF1</em> alleles occurs, indicating that this is the primary tumor cell of the neurofibroma [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/13,45,46\" class=\"abstract_t\">13,45,46</a>]. (See <a href=\"#H1815266\" class=\"local\">'Soft tissue sarcomas'</a> below.)</p><p>Neurofibromas may appear as focal growths or extend longitudinally along a nerve and involve multiple fascicles. The latter are referred to as plexiform neurofibromas. Neurofibromas may be located in the skin (cutaneous neurofibromas), along peripheral nerves under the skin or deeper inside the body, and along nerve roots adjacent to the spine.</p><p>The number and size of all types of neurofibromas may increase during pregnancy, suggesting that these tumors have a hormone-responsive component. In a report of 247 pregnancies in 105 women, growth of new lesions and enlargement of existing lesions were reported in 60 and 55 percent of cases, respectively [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/47\" class=\"abstract_t\">47</a>].</p><p class=\"headingAnchor\" id=\"H19620730\"><span class=\"h4\">Cutaneous</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Discrete cutaneous neurofibromas are the most common type. They consist of soft, fleshy, sessile or pedunculated tumors (<a href=\"image.htm?imageKey=ALLRG%2F96127\" class=\"graphic graphic_picture graphicRef96127 \">picture 6</a>) [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/48\" class=\"abstract_t\">48</a>]. They move with the skin on examination and are not tender. Some are located within the dermis and can be palpated as a soft spot in the skin, often with an overlying violaceous discoloration. These cutaneous lesions usually begin to appear just before or during adolescence, although small lesions can be seen in younger children, especially if the skin is viewed with side lighting. They tend to increase in size and number with age and vary in number from just a few to thousands, with the highest density occurring over the trunk.</p><p>Cutaneous neurofibromas are benign and do not carry an increased risk of malignant transformation, but they often represent a major cosmetic problem in adults (<a href=\"image.htm?imageKey=DERM%2F82613\" class=\"graphic graphic_picture graphicRef82613 \">picture 7</a>). Pruritus associated with accelerated growth of neurofibromas may be a prominent and distressing symptom.</p><p class=\"headingAnchor\" id=\"H16375435\"><span class=\"h4\">Plexiform</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Plexiform neurofibromas may be located superficially and associated with overgrowth of skin and soft tissues (<a href=\"image.htm?imageKey=ALLRG%2F96123\" class=\"graphic graphic_picture graphicRef96123 \">picture 8</a>), may be located deep inside the body, or may have both superficial and deep components. Cutaneous involvement tends to be diffuse, with no discernible nerve fibers, although small plaques of cutaneous plexiform tumors may have palpable cords of thickened nerves. Deeper plexiform neurofibromas tend to appear as thickened nerves and can grow into a complex mass consisting of a network of enlarged nerves. The lesions are usually congenital and tend to grow most rapidly during childhood [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/49\" class=\"abstract_t\">49</a>]. Whole body imaging reveals plexiform neurofibromas in approximately 50 percent of patients with NF1 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/50\" class=\"abstract_t\">50</a>].</p><p>Plexiform neurofibromas represent a major cause of morbidity and disfigurement in individuals with NF1, and symptomatic plexiform neurofibromas are associated with increased mortality [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/51\" class=\"abstract_t\">51</a>]. Plexiform neurofibromas may compress the airway or spinal cord and can transform into malignant peripheral nerve sheath tumors (MPNSTs). The most common feature of malignant transformation of an existing plexiform neurofibroma is a painful, expanding lesion [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/52\" class=\"abstract_t\">52</a>]. (See <a href=\"#H16376385\" class=\"local\">'Malignant peripheral nerve sheath tumors'</a> below.)</p><p class=\"headingAnchor\" id=\"H19620744\"><span class=\"h4\">Nodular</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nodular neurofibromas are discrete lesions that may grow under the skin, where they appear as firm, rubbery masses that may be tender, or occur deeper inside the body. Some can enlarge to the point where they compress surrounding structures or cause pain, but they do not tend to invade surrounding tissues like plexiform neurofibromas. Nodular neurofibromas can also transform into MPNST.</p><p class=\"headingAnchor\" id=\"H1815198\"><span class=\"h3\">Optic pathway gliomas</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>OPGs occur in 15 percent of children younger than six years of age with NF1 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/53\" class=\"abstract_t\">53</a>]. They rarely occur in older children and adults [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/54,55\" class=\"abstract_t\">54,55</a>]. OPGs are typically low-grade pilocytic astrocytomas [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/56\" class=\"abstract_t\">56</a>]. They can arise anywhere along the anterior visual pathway to the optic radiations and involve the optic nerves, chiasm, and postchiasmal optic tracts (<a href=\"image.htm?imageKey=RADIOL%2F100713\" class=\"graphic graphic_diagnosticimage graphicRef100713 \">image 1</a>). (See <a href=\"topic.htm?path=optic-pathway-glioma\" class=\"medical medical_review\">&quot;Optic pathway glioma&quot;</a> and <a href=\"topic.htm?path=neurofibromatosis-type-1-nf1-management-and-prognosis#H196003573\" class=\"medical medical_review\">&quot;Neurofibromatosis type 1 (NF1): Management and prognosis&quot;, section on 'Optic pathway gliomas'</a>.)</p><p>Many children with NF1 and OPGs have normal vision. A minority of children become symptomatic, with progressive vision loss associated with an expanding lesion [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/53,57-59\" class=\"abstract_t\">53,57-59</a>]. Symptoms and signs of OPG may include decreased visual acuity or color vision, abnormal pupillary function, proptosis, and optic nerve atrophy [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/60-62\" class=\"abstract_t\">60-62</a>].</p><p class=\"headingAnchor\" id=\"H2690166103\"><span class=\"h4\">Premature or delayed puberty due to OPGs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Children with advanced tumors involving the optic chiasm occasionally present with either premature or delayed puberty caused by hypothalamic involvement [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/59\" class=\"abstract_t\">59</a>]. Detecting precocious puberty early in patients with NF1 is important because it may indicate the presence of a clinically significant optic pathway glioma (OPG), although abnormal puberty can occur in the absence of OPG. In addition, treatment can minimize the complications of accelerated linear bone growth and premature development of secondary sexual characteristics. One of the earliest signs of precocious puberty is accelerated linear growth, which highlights the importance of maintaining accurate growth charts using standards for children with NF1 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/63-66\" class=\"abstract_t\">63-66</a>]. (See <a href=\"topic.htm?path=definition-etiology-and-evaluation-of-precocious-puberty\" class=\"medical medical_review\">&quot;Definition, etiology, and evaluation of precocious puberty&quot;</a> and <a href=\"#H19620786\" class=\"local\">'Short stature'</a> below.)</p><p class=\"headingAnchor\" id=\"H1815234\"><span class=\"h3\">Other central nervous system neoplasms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to OPGs, individuals with NF1 are at an increased risk for developing other CNS neoplasms, particularly astrocytomas and brainstem gliomas [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/59,67-69\" class=\"abstract_t\">59,67-69</a>]. Although astrocytomas usually arise in early childhood (mean age at diagnosis 4.5 years), the risk persists into adulthood [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/54\" class=\"abstract_t\">54</a>]. The most frequent clinical presentation is that of increased intracranial pressure [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/59\" class=\"abstract_t\">59</a>], although lesions are often asymptomatic and are noted as incidental findings if brain imaging is performed. Most children with NF1 and brainstem gliomas are symptomatic [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/69\" class=\"abstract_t\">69</a>]. </p><p class=\"headingAnchor\" id=\"H1815266\"><span class=\"h3\">Soft tissue sarcomas</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with NF1 are at an increased risk of developing soft tissue sarcomas, such as MPNSTs and rhabdomyosarcoma (RMS).</p><p class=\"headingAnchor\" id=\"H16376385\"><span class=\"h4\">Malignant peripheral nerve sheath tumors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>MPNSTs, previously called neurofibrosarcomas, usually arise within pre-existing plexiform or nodular neurofibromas that have undergone malignant transformation. The primary care provider should be alert to the possibility of this highly malignant tumor, particularly in teenagers and young adults. The first presentation of malignant transformation often is development of significant and constant pain, change in consistency, or rapid growth of a nodule within an existing plexiform neurofibroma [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/18,70,71\" class=\"abstract_t\">18,70,71</a>]. Positron emission tomography (PET) imaging with fluorodeoxyglucose may be helpful in distinguishing MPNST from benign plexiform or nodular neurofibromas [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/72\" class=\"abstract_t\">72</a>]. The lifetime risk of developing an MPNST in patients with NF1 ranges from 5 to 13 percent [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/73-76\" class=\"abstract_t\">73-76</a>]. Among children with MPNSTs, 20 to 50 percent have NF1 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/70,73,77\" class=\"abstract_t\">70,73,77</a>]. Patients with NF1 tend to have larger tumors at diagnosis [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/78,79\" class=\"abstract_t\">78,79</a>]. MPNSTs are discussed in greater detail separately. (See <a href=\"topic.htm?path=peripheral-nerve-tumors#H30353503\" class=\"medical medical_review\">&quot;Peripheral nerve tumors&quot;, section on 'Malignant peripheral nerve sheath tumors'</a> and <a href=\"topic.htm?path=neurofibromatosis-type-1-nf1-management-and-prognosis#H196003579\" class=\"medical medical_review\">&quot;Neurofibromatosis type 1 (NF1): Management and prognosis&quot;, section on 'Malignant peripheral nerve sheath tumors'</a>.)</p><p class=\"headingAnchor\" id=\"H16376392\"><span class=\"h4\">Rhabdomyosarcoma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>RMS is encountered more frequently in patients with NF1 than in the general population [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/80-82\" class=\"abstract_t\">80-82</a>]. RMS tends to present at an early age and often arises in a genitourinary site [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/80\" class=\"abstract_t\">80</a>]. (See <a href=\"topic.htm?path=rhabdomyosarcoma-in-childhood-and-adolescence-epidemiology-pathology-and-molecular-pathogenesis\" class=\"medical medical_review\">&quot;Rhabdomyosarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H16376399\"><span class=\"h4\">Gastrointestinal stromal tumors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with NF1 are also at an increased risk of developing soft tissue sarcomas that arise within the stromal compartment of the gastrointestinal tract, termed gastrointestinal stromal tumors (GISTs) [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/83-85\" class=\"abstract_t\">83-85</a>]. In the setting of NF1, GISTs frequently occur in the small intestine (more than 70 percent), are often multiple, and have a different molecular pathology. (See <a href=\"topic.htm?path=epidemiology-classification-clinical-presentation-prognostic-features-and-diagnostic-work-up-of-gastrointestinal-stromal-tumors-gist\" class=\"medical medical_review\">&quot;Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal stromal tumors (GIST)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H21346439\"><span class=\"h4\">Glomus tumors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Glomus tumors arise in the tips of the fingers and toes under the nail bed and present with pain, tenderness, and sensitivity to cold. They are associated with NF1 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/86\" class=\"abstract_t\">86</a>] and are important to recognize because the pain is readily relieved by surgical removal of the tumor.</p><p class=\"headingAnchor\" id=\"H1815318\"><span class=\"h3\">Other tumors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>NF1 patients have an increased risk of certain other malignancies, such as juvenile myelomonocytic leukemia of childhood and pheochromocytoma, although genetic etiologies other than NF1 are more common causes of these malignancies [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/4\" class=\"abstract_t\">4</a>]. Women with NF1, particularly those under 50 years of age, are at increased risk of breast cancer [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/40,87-90\" class=\"abstract_t\">40,87-90</a>]. Whether other common malignancies occur at higher rates in patients with NF1 is uncertain [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/42,91\" class=\"abstract_t\">42,91</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-chronic-myeloid-leukemia#H11\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of chronic myeloid leukemia&quot;, section on 'Juvenile myelomonocytic leukemia'</a>.)</p><p class=\"headingAnchor\" id=\"H19620765\"><span class=\"h2\">Bone abnormalities</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bony abnormalities in NF1 include pseudoarthrosis and bone dysplasia, which are part of the United States National Institutes of Health (NIH) Consensus Conference criteria for the disease [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/32,92,93\" class=\"abstract_t\">32,92,93</a>], as well as short stature, scoliosis, nonossifying fibromas, and osteoporosis [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/94,95\" class=\"abstract_t\">94,95</a>]. (See <a href=\"#H20886927\" class=\"local\">'Diagnostic criteria'</a> below.)</p><p class=\"headingAnchor\" id=\"H19620772\"><span class=\"h3\">Long bone dysplasia and pseudoarthrosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Long bone dysplasia typically presents in infants or young children as anterolateral bowing of the tibia, which progresses to narrowing of the medullary canal, cortical thickening, and fracture [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/96,97\" class=\"abstract_t\">96,97</a>]. The diagnosis may be overlooked until pathologic fractures occur with weight bearing or when walking is first attempted in toddlers. Approximately one-half of fractures occur before the patient is two years of age.</p><p>A pseudoarthrosis is a false joint that forms when there is nonunion of bone fragments at the site of a long bone fracture. It severely compromises function in the affected limb. Pseudoarthrosis in NF1 results from impaired healing due to bone dysplasia [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/18\" class=\"abstract_t\">18</a>]. Long bone pseudoarthrosis occurs in infancy in approximately 5 percent of patients with NF1 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/96\" class=\"abstract_t\">96</a>]. It has a male predominance (1.7:1). NF1 is the most common cause of long bone pseudoarthrosis, accounting for 50 to 80 percent of cases. Thus, evaluation for NF1 should be performed in a child with this condition. Management is complex and may necessitate amputation to allow the toddler to walk. The Children's Tumor Foundation has published guidelines for management of children with NF1 and pseudoarthrosis [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/98\" class=\"abstract_t\">98</a>].</p><p class=\"headingAnchor\" id=\"H19620779\"><span class=\"h3\">Other bone lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other skeletal lesions include vertebral defects, such as scalloping caused by dural ectasia, nonossifying fibromas within long bones, and sphenoid wing dysplasia, which may present as facial asymmetry [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/93\" class=\"abstract_t\">93</a>]. Young children with NF1 may have a hair whorl overlying an area of vertebral dysplasia [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/99\" class=\"abstract_t\">99</a>].</p><p class=\"headingAnchor\" id=\"H19620786\"><span class=\"h3\">Short stature</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Children with NF1 frequently have short stature. In a database of 569 white North American patients with NF1, 13 percent had a height &ge;2 standard deviations below the population mean [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/63\" class=\"abstract_t\">63</a>]. Growth curves for children with NF1 are available and can aid the clinician in determining if the degree of short stature is consistent with the diagnosis of NF1 or is more severe [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/63,64\" class=\"abstract_t\">63,64</a>]. The latter suggests an additional cause and requires evaluation. (See <a href=\"topic.htm?path=diagnostic-approach-to-children-and-adolescents-with-short-stature\" class=\"medical medical_review\">&quot;Diagnostic approach to children and adolescents with short stature&quot;</a> and <a href=\"topic.htm?path=causes-of-short-stature\" class=\"medical medical_review\">&quot;Causes of short stature&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H19620793\"><span class=\"h3\">Scoliosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Scoliosis occurs in 10 to 25 percent of individuals with NF1 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/36,57\" class=\"abstract_t\">36,57</a>]. This condition frequently becomes apparent at 6 to 10 years of age or in early adolescence. Scoliosis in children with NF1 most commonly affects the thoracic spine. (See <a href=\"topic.htm?path=adolescent-idiopathic-scoliosis-clinical-features-evaluation-and-diagnosis\" class=\"medical medical_review\">&quot;Adolescent idiopathic scoliosis: Clinical features, evaluation, and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H19620800\"><span class=\"h3\">Osteoporosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Individuals with NF1 have lower bone density per age compared with general population controls. Characterization of 74 NF1 patients (children and young adults) by dual energy x-ray absorptiometry (DXA) scans found statistically significant and generalized reduction in bone mass [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/94\" class=\"abstract_t\">94</a>]. The severity of decreased bone density can range from osteopenia to osteoporosis. The etiology of this decrease in bone density is unknown. A survey from Finland revealed an increased risk of fractures in both children and adults over the age of 40 years with NF1 (threefold and fivefold increased relative risk, respectively) compared with population controls of similar age and gender distribution [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/100\" class=\"abstract_t\">100</a>].</p><p class=\"headingAnchor\" id=\"H1812090\"><span class=\"h2\">Neurologic abnormalities</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Neurologic disorders include cognitive deficits, learning disabilities, and seizures. Gross and fine motor developmental delays are also seen [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/101\" class=\"abstract_t\">101</a>]. Macrocephaly is a common feature.</p><p class=\"headingAnchor\" id=\"H1812097\"><span class=\"h3\">Cognitive deficits and learning disabilities</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cognitive deficits, learning disabilities, and autism spectrum disorders occur with higher frequency in children with NF1 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/102-104\" class=\"abstract_t\">102-104</a>]. A study of 81 children with NF1 found moderate-to-severe impairment involving one or more domains of cognitive function in 66 (81 percent) [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/105\" class=\"abstract_t\">105</a>]. Intelligence quotient (IQ) scores are 5 to 10 points lower in children with NF1 compared with the general population or unaffected sibling controls [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/106\" class=\"abstract_t\">106</a>]. The incidence of intellectual disability (full scale IQ &lt;70) in this disorder is 4 to 8 percent, only slightly higher than that of the general population (2 to 3 percent). Thus, a child with NF1 and intellectual disability should be evaluated for other causes of cognitive impairment (eg, fragile X syndrome). (See <a href=\"topic.htm?path=fragile-x-syndrome-clinical-features-and-diagnosis-in-children-and-adolescents\" class=\"medical medical_review\">&quot;Fragile X syndrome: Clinical features and diagnosis in children and adolescents&quot;</a>.)</p><p>One-half of the children in one series performed poorly on tasks of reading, spelling, and mathematics, but only 20 percent had specific learning disabilities (defined by discrepancy between ability [IQ] and academic achievement) [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/105\" class=\"abstract_t\">105</a>]. Specific learning disabilities occur in up to 65 percent of patients with NF1 in other series [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/102,106\" class=\"abstract_t\">102,106</a>]. Affected children demonstrate a range of neuropsychologic impairments, including poor performance on nonverbal learning problems (ie, difficulty with written work, poor attention, and decreased organizational skills); tests of visuospatial function; and language-based learning tasks (ie, reading and spelling) [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/106\" class=\"abstract_t\">106</a>]. Attention deficit hyperactivity disorder (ADHD) occurs in 38 to 39 percent of children with NF1 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/105,107\" class=\"abstract_t\">105,107</a>]. Executive function impairment in the areas of planning and problem solving that are not directly related to inattention level are seen [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/108\" class=\"abstract_t\">108</a>]. Problems with speech articulation are also common. (See <a href=\"topic.htm?path=neurofibromatosis-type-1-nf1-management-and-prognosis#H196003603\" class=\"medical medical_review\">&quot;Neurofibromatosis type 1 (NF1): Management and prognosis&quot;, section on 'Cognitive and learning deficits'</a> and <a href=\"topic.htm?path=specific-learning-disabilities-in-children-clinical-features\" class=\"medical medical_review\">&quot;Specific learning disabilities in children: Clinical features&quot;</a> and <a href=\"topic.htm?path=specific-learning-disabilities-in-children-evaluation\" class=\"medical medical_review\">&quot;Specific learning disabilities in children: Evaluation&quot;</a> and <a href=\"topic.htm?path=attention-deficit-hyperactivity-disorder-in-children-and-adolescents-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1812111\"><span class=\"h3\">Seizures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Seizures are approximately twice as common in patients with NF1 compared with the general population, with a prevalence of approximately 4 to 6 percent [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/109-111\" class=\"abstract_t\">109-111</a>]. Seizures can be of any type and begin at any age. Focal seizures may be due to an intracranial neoplasm [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/111\" class=\"abstract_t\">111</a>]. Thus, new seizures should prompt repeat neuroimaging, even if previous imaging was normal. (See <a href=\"topic.htm?path=seizures-and-epilepsy-in-children-classification-etiology-and-clinical-features\" class=\"medical medical_review\">&quot;Seizures and epilepsy in children: Classification, etiology, and clinical features&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1812118\"><span class=\"h3\">Macrocephaly</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Head size is generally larger in persons with NF1. This may present as relative macrocephaly compared with height or absolute macrocephaly [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/63,112\" class=\"abstract_t\">63,112</a>]. It is caused by increased brain volume. Rarely, hydrocephalus may occur due to aqueductal stenosis. (See <a href=\"#H1810704\" class=\"local\">'Increased brain volume (megalencephaly)'</a> below.)</p><p class=\"headingAnchor\" id=\"H1812125\"><span class=\"h3\">Peripheral neuropathy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Peripheral neuropathy is much less common in NF1 than in neurofibromatosis type 2 (NF2), with reports of nerve compression in up to 4 percent of patients and spinal root compression in up to 3 percent in patients with NF1 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/36,57,67,113\" class=\"abstract_t\">36,57,67,113</a>]. By comparison, clinical symptoms of peripheral neuropathy occur in almost 50 percent of patients with NF2 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/113\" class=\"abstract_t\">113</a>]. Nevertheless, peripheral neuropathy can be a severe complication of NF1 that is associated with frequent morbidity related to spinal complications and development of MPNSTs [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/114\" class=\"abstract_t\">114</a>], though polyneuropathy can occur in the absence of a compressive lesion [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/115\" class=\"abstract_t\">115</a>]. (See <a href=\"topic.htm?path=neurofibromatosis-type-2\" class=\"medical medical_review\">&quot;Neurofibromatosis type 2&quot;</a> and <a href=\"#H16376385\" class=\"local\">'Malignant peripheral nerve sheath tumors'</a> above.)</p><p class=\"headingAnchor\" id=\"H1817071\"><span class=\"h2\">Hypertension</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hypertension is a frequent finding in adults with NF1 and may develop during childhood. Hypertension is considered essential in most cases, but vascular lesions producing renovascular hypertension are more frequent in NF1 patients. Thus, evaluation for renovascular causes should be initiated in children with NF1 and hypertension [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/57,116\" class=\"abstract_t\">57,116</a>]. Renovascular lesions can be detected in patients who are still normotensive. The frequency with which such patients will develop hypertension is not known. A much less common cause of hypertension in NF1 is pheochromocytoma, which has been clinically identified in 0.1 to 5.7 percent of patients. (See <a href=\"topic.htm?path=definition-and-diagnosis-of-hypertension-in-children-and-adolescents\" class=\"medical medical_review\">&quot;Definition and diagnosis of hypertension in children and adolescents&quot;</a> and <a href=\"topic.htm?path=overview-of-hypertension-in-adults\" class=\"medical medical_review\">&quot;Overview of hypertension in adults&quot;</a> and <a href=\"topic.htm?path=pheochromocytoma-and-paraganglioma-in-children\" class=\"medical medical_review\">&quot;Pheochromocytoma and paraganglioma in children&quot;</a> and <a href=\"#H1815318\" class=\"local\">'Other tumors'</a> above and <a href=\"topic.htm?path=neurofibromatosis-type-1-nf1-management-and-prognosis#H196003536\" class=\"medical medical_review\">&quot;Neurofibromatosis type 1 (NF1): Management and prognosis&quot;, section on 'In patients with severe hypertension'</a>.)</p><p class=\"headingAnchor\" id=\"H13147715\"><span class=\"h2\">Other manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Very rarely, patients may develop cardiovascular complaints or airway compromise due to mediastinal neurofibromas or MPNST metastases to the heart and lung [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/117-119\" class=\"abstract_t\">117-119</a>]. Pulmonary hypertension [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/120-122\" class=\"abstract_t\">120-122</a>], pulmonary artery stenosis [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/123\" class=\"abstract_t\">123</a>], interstitial lung disease [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/124\" class=\"abstract_t\">124</a>], and bullous lung disease [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/125\" class=\"abstract_t\">125</a>] have also been reported. Pulmonary embolism and acute myocardial infarction have occurred in patients with both NF1 and pheochromocytoma [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/126,127\" class=\"abstract_t\">126,127</a>]. Other vascular lesions may cause stenosis of major vessels, including the internal carotid, resulting in moyamoya syndrome. In rare instances, arterial dissection can occur, sometimes leading to life-threatening hemorrhage [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/128\" class=\"abstract_t\">128</a>]. (See <a href=\"#H16375435\" class=\"local\">'Plexiform'</a> above and <a href=\"#H16376385\" class=\"local\">'Malignant peripheral nerve sheath tumors'</a> above and <a href=\"#H1815318\" class=\"local\">'Other tumors'</a> above and <a href=\"topic.htm?path=moyamoya-disease-etiology-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Moyamoya disease: Etiology, clinical features, and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1817163\"><span class=\"h2\">Segmental NF1</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Segmental NF1 is due to mosaicism for an <em>NF1</em> gene mutation. The presentation of segmental and generalized NF1 is similar with regard to the age of appearance of the specific features, with a few exceptions [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/4,129\" class=\"abstract_t\">4,129</a>]. In segmental NF1, pigmentary features and plexiform neurofibromas tend to present in children, while dermal neurofibromas develop in adults. Lisch nodules may be present in one or both eyes. In most patients, the affected area is limited to one side, with involvement ranging from a narrow strip to one-half of the body [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/4\" class=\"abstract_t\">4</a>]. More serious complications of NF1, such as OPGs, pseudoarthrosis, plexiform neurofibromas, and learning difficulties, are uncommon in patients with segmental NF1, occurring in 5.6 percent in one series of 124 patients [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/4\" class=\"abstract_t\">4</a>].</p><p class=\"headingAnchor\" id=\"H1810690\"><span class=\"h1\">NEUROIMAGING FINDINGS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Neuroimaging abnormalities are frequently detected in patients with NF1 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/130\" class=\"abstract_t\">130</a>]. These include NF-associated bright spots and increased brain volume.</p><p class=\"headingAnchor\" id=\"H1810697\"><span class=\"h2\">NF-associated bright spots</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Focal areas of increased signal intensity were first identified on T2-weighted magnetic resonance imaging (MRI) of the brain in children with NF1. The term &quot;unidentified bright objects&quot; (UBOs) is discouraged because it can be upsetting to parents. Bright spots are seen commonly in children with NF1 but may disappear in adulthood [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/7\" class=\"abstract_t\">7</a>]. They occur most often in the basal ganglia, cerebellum, brainstem, and subcortical white matter and are thought to represent increased fluid within the myelin associated with dysplastic glial proliferation [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/131,132\" class=\"abstract_t\">131,132</a>]. They do not behave in a malignant or premalignant manner and are not associated with focal neurologic deficits. They are not part of the United States National Institutes of Health (NIH) diagnostic criteria [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/132,133\" class=\"abstract_t\">132,133</a>].</p><p>Data are conflicting on the relationship between NF-associated bright spots and cognitive function. In one report, 25 of 40 children (62 percent) with NF1 had bright spots present on MRI [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/134\" class=\"abstract_t\">134</a>]. These patients had significantly lower intelligence quotient (IQ) and language scores and impaired visuomotor integration and coordination compared with children without them. In another study, the number of locations containing spots accounted for much of the lowering of IQ scores in NF1 patients compared with unaffected siblings [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/135\" class=\"abstract_t\">135</a>]. However, in a third series, these lesions were not associated with intellectual impairment [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/132\" class=\"abstract_t\">132</a>]. (See <a href=\"#H1812097\" class=\"local\">'Cognitive deficits and learning disabilities'</a> above.)</p><p class=\"headingAnchor\" id=\"H1810704\"><span class=\"h2\">Increased brain volume (megalencephaly)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Brain volumes are increased in patients with NF1 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/112,130,136,137\" class=\"abstract_t\">112,130,136,137</a>]. (See <a href=\"#H1812118\" class=\"local\">'Macrocephaly'</a> above and <a href=\"#H1812097\" class=\"local\">'Cognitive deficits and learning disabilities'</a> above.)</p><p class=\"headingAnchor\" id=\"H1810726\"><span class=\"h2\">Cerebrovascular dysplasia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several retrospective series have noted abnormal cerebral vasculature (eg, moyamoya syndrome, intracranial aneurysm) in 2 to 6 percent of children with NF1 who underwent neuroimaging [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/138-140\" class=\"abstract_t\">138-140</a>]. Most patients were asymptomatic despite angiographic progression, but some required surgery for revascularization.</p><p class=\"headingAnchor\" id=\"H20886015\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of NF1 is based upon the presence of characteristic clinical features (<a href=\"image.htm?imageKey=PEDS%2F63696\" class=\"graphic graphic_table graphicRef63696 \">table 2</a>). Genetic testing is often not required to make the diagnosis but can be helpful in confirming the diagnosis for children who do not meet diagnostic criteria or only demonstrate caf&eacute;-au-lait macules and axillary freckling.</p><p>Children suspected of having NF1 should be evaluated by a multidisciplinary team that includes pediatric neurology, genetics, and ophthalmology. This team should examine the child for diagnostic criteria and treatable complications, provide anticipatory guidance, and refer to specialists as needed. Both an expert panel [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/92\" class=\"abstract_t\">92</a>] and the Genetics Committee of the American Academy of Pediatrics have published diagnostic and health supervision <a href=\"http://pediatrics.aappublications.org/content/121/3/633.full.pdf&amp;token=ib7xmi67agj/1g9csAHCq62IAEujo7JY1htcBewFLQ/4kJOmEFoODbht13rqLBsmDnZIwCtK2ICfkY9stMbJLP/1ryz82YMMa7tvKvA46i4=&amp;TOPIC_ID=2939\" target=\"_blank\" class=\"external\">guidelines</a> for children with NF1 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/66\" class=\"abstract_t\">66</a>].</p><p>The initial screening evaluation should confirm the diagnosis by identifying clinical features of NF1. History should be obtained regarding symptoms associated with the disorder, such as pain, visual complaints, weakness or neurologic deficits, headaches, and seizures. The developmental history and school progress should be reviewed. Physical examination should focus on skin, skeletal, and neurologic systems. Ophthalmologic evaluation should be performed to identify Lisch nodules and early signs of optic pathway glioma (OPG). (See <a href=\"#H20886007\" class=\"local\">'Clinical manifestations'</a> above and <a href=\"#H20886927\" class=\"local\">'Diagnostic criteria'</a> below.)</p><p class=\"headingAnchor\" id=\"H20886927\"><span class=\"h2\">Diagnostic criteria</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnostic criteria developed by the United States National Institutes of Health (NIH) Consensus Conference in 1987 and updated in 1997 are based upon specific clinical features of NF1 (<a href=\"image.htm?imageKey=PEDS%2F63696\" class=\"graphic graphic_table graphicRef63696 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/32,92,93\" class=\"abstract_t\">32,92,93</a>]. According to these criteria, <strong>at least two</strong> of the following clinical features must be present to make the diagnosis of NF1:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Six or more caf&eacute;-au-lait macules &gt;5 mm in diameter in prepubertal and &gt;15 mm in diameter in postpubertal individuals. For each lesion, the longest diameter is measured.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Two or more neurofibromas of any type or one plexiform neurofibroma (<a href=\"image.htm?imageKey=ALLRG%2F55032\" class=\"graphic graphic_picture graphicRef55032 \">picture 5</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Freckling in the axillary or inguinal regions.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Optic glioma.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Two or more Lisch nodules (iris hamartomas).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A distinctive bony lesion, such as sphenoid dysplasia or thickening of the long bone cortex with or without pseudoarthrosis.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A first-degree relative (parent, sibling, or offspring) with NF1 based upon the above criteria.</p><p/><p>The NIH diagnostic criteria are both highly specific and sensitive in all but the youngest children [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/32,36\" class=\"abstract_t\">32,36</a>], with 97 percent of patients meeting the diagnostic criteria by eight years of age and the remainder meeting criteria by 20 years of age in a study of 1893 NF1 patients younger than 21 years of age [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/32\" class=\"abstract_t\">32</a>]. Approximately 46 percent of sporadic NF1 patients failed to meet the criteria by one year of age. Thus, young children who have only one clinical manifestation and no family history of NF1 should continue to be monitored for appearance of other manifestations since a definitive diagnosis usually can be made by the time the child is four years of age. Genetic testing can be considered to make a molecular diagnosis. In one report of 41 children one month to 14 years of age with six or more caf&eacute;-au-lait macules on the initial visit, a diagnosis of NF1 was eventually made in approximately 50 percent, although, at the time of the study, the diagnosis remained unresolved in eight patients [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/33\" class=\"abstract_t\">33</a>].</p><p class=\"headingAnchor\" id=\"H20886947\"><span class=\"h2\">Genetic testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Genetic testing can be performed to confirm the diagnosis in questionable cases and to help direct screening of family members (ie, perform targeted testing for the mutation identified in the proband rather than a comprehensive mutation analysis of the entire gene). It is required for prenatal or preimplantation diagnosis. A positive <em>NF1</em> mutation test does not predict the severity or complications of the disorder. (See <a href=\"#H20885999\" class=\"local\">'Pathogenesis'</a> above.)</p><p>Mutations associated with the clinical diagnosis of NF1 disrupt the function of the <em>NF1</em> gene. Because of the large size of the gene and the heterogeneity of mutations, molecular testing includes sequencing of all of the coding exons as well as tests for deletions or rearrangements of a portion or the entire gene. Molecular testing is clinically available and is reported to find the causative DNA mutation in approximately 95 percent of patients who carry the clinical diagnosis of NF1 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/141\" class=\"abstract_t\">141</a>]. Thus, a negative test does not completely exclude the diagnosis. A negative test may also represent mosaicism for the mutation (for example, in segmental NF1 where blood maybe negative) or the possibility of a different disorder. (See <a href=\"#H20886023\" class=\"local\">'Differential diagnosis'</a> below.)</p><p>Individuals with other conditions, including Legius syndrome [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/142,143\" class=\"abstract_t\">142,143</a>] and constitutional mismatch repair-deficiency (CMMR-D) syndrome [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/144\" class=\"abstract_t\">144</a>], may manifest both caf&eacute;-au-lait macules and axillary freckling, and those with Noonan syndrome may present with caf&eacute;-au-lait macules [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/145\" class=\"abstract_t\">145</a>]. Thus, there is increasing use of genetic testing in the diagnosis of NF1 for patients who meet only these two NIH criteria in addition to those with only one NIH criterion. A positive genetic test may shorten the period of diagnostic uncertainty. In addition, appropriate screening evaluations (eg, ophthalmic screens) are initiated promptly if the test is positive for an <em>NF1</em> mutation. If the <em>NF1</em> mutation testing is negative, then the diagnostic laboratory may perform <em>SPRED1</em> (sprouty-related EVH1 <span class=\"nowrap\">[enabled/vasodilator-stimulated</span> phosphoprotein homology 1] domain-containing protein 1) mutation testing to evaluate for Legius syndrome. If both are negative, then genetic testing of the four mismatch repair genes or Noonan syndrome should be considered. The parents of young children with multiple caf&eacute;-au-lait macules alone should understand the risks and benefits of genetic analysis before proceeding with testing. (See <a href=\"#H20886023\" class=\"local\">'Differential diagnosis'</a> below.)</p><p class=\"headingAnchor\" id=\"H13148115\"><span class=\"h2\">Screening family members</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A detailed family history should be obtained to detect possible symptoms of NF1 when the diagnosis is made in a child. When possible, parents and siblings should be examined for the characteristic signs (<a href=\"image.htm?imageKey=PEDS%2F63696\" class=\"graphic graphic_table graphicRef63696 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/92\" class=\"abstract_t\">92</a>]. This evaluation includes a complete examination of the skin and a slit-lamp examination of the eyes because of the variable expressivity characteristic of this disorder. (See <a href=\"#H20885999\" class=\"local\">'Pathogenesis'</a> above.)</p><p>Genetic screening of family members is discussed above. (See <a href=\"#H20886947\" class=\"local\">'Genetic testing'</a> above.)</p><p class=\"headingAnchor\" id=\"H19621752\"><span class=\"h2\">Prenatal testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Amniocentesis or chorionic villus sampling can be performed to obtain a sample for genotyping the fetus if the precise mutation of an affected family member with NF1 is known. Preimplantation genetic diagnosis (PGD) to identify those embryos that do not carry a known familial <em>NF1</em> mutation is also possible [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/146\" class=\"abstract_t\">146</a>]. (See <a href=\"topic.htm?path=neurofibromatosis-type-1-nf1-management-and-prognosis#H196003663\" class=\"medical medical_review\">&quot;Neurofibromatosis type 1 (NF1): Management and prognosis&quot;, section on 'Genetic counseling'</a>.)</p><p class=\"headingAnchor\" id=\"H20886023\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of NF1 includes Legius syndrome, constitutional mismatch repair-deficiency (CMMR-D) syndrome, neurofibromatosis type 2 (NF2), and Noonan syndrome. Genetic testing can distinguish NF1 from these other syndromes.</p><p class=\"headingAnchor\" id=\"H20887086\"><span class=\"h2\">Legius syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical features of Legius syndrome include a subset of those of NF1 (multiple caf&eacute;-au-lait macules, axillary freckling, and macrocephaly) but importantly lack neurofibromas and central nervous system (CNS) tumors [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/143,147\" class=\"abstract_t\">143,147</a>]. Legius syndrome is an autosomal dominant NF1-like disorder that results from germline loss-of-function mutations in <em>SPRED1 </em>(sprouty-related EVH1 <span class=\"nowrap\">[enabled/vasodilator-stimulated</span> phosphoprotein homology 1] domain-containing protein 1) [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/142,143\" class=\"abstract_t\">142,143</a>]. SPRED1 is a member of the <span class=\"nowrap\">SPROUTY/SPRED</span> family of proteins that act as negative regulators of RAS-RAF kinase interaction and mitogen-activated protein kinase (MAPK) signaling. Melanocytes from a caf&eacute;-au-lait spot demonstrated both the germline <em>SPRED1</em> mutation and an acquired somatic mutation in the wild-type <em>SPRED1</em> allele, suggesting that complete SPRED1 inactivation is needed to generate a caf&eacute;-au-lait spot in this syndrome [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/142\" class=\"abstract_t\">142</a>].</p><p class=\"headingAnchor\" id=\"H10683318\"><span class=\"h2\">Constitutional mismatch repair-deficiency syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CMMR-D syndrome is a rare, autosomal recessive disorder caused by inheritance of deleterious mutations in both copies of one of the four mismatch repair genes [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/144\" class=\"abstract_t\">144</a>]. The main clinical manifestation that CMMR-D shares with NF1 is caf&eacute;-au-lait macules. Axillary freckling and Lisch nodules have also been reported in CMMR-D. The primary clinical difference between the two disorders is the types of malignancies seen with each. In CMMR-D, hematologic malignancies typically develop in infancy to early childhood, brain tumors (primarily glioblastoma) in mid-childhood, and colorectal cancer in adolescence to young adulthood. A variety of other tumors (eg, rhabdomyosarcoma [RMS] and optic pathway glioma [OPG]) are less commonly seen in CMMR-D [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/144,148,149\" class=\"abstract_t\">144,148,149</a>]. Heterozygous mutations in one of the MMR genes cause Lynch syndrome (hereditary nonpolyposis colon cancer). (See <a href=\"topic.htm?path=lynch-syndrome-hereditary-nonpolyposis-colorectal-cancer-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H10683326\"><span class=\"h2\">Neurofibromatosis type 2</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>NF2 and NF1 are caused by mutations in genes on different chromosomes that encode proteins of distinct function. Nonetheless, partial overlap in the clinical manifestations of these inherited disorders can occasionally lead to confusion. (See <a href=\"topic.htm?path=neurofibromatosis-type-2\" class=\"medical medical_review\">&quot;Neurofibromatosis type 2&quot;</a>.)</p><p>Key differences between NF1 and NF2 include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Caf&eacute;-au-lait macules can be seen but are much less frequent in NF2, and Lisch nodules are not seen.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The schwannomas associated with NF2 do not undergo malignant transformation into a malignant peripheral nerve sheath tumor (MPNST).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The spinal root tumors that are seen with both NF2 and NF1 are schwannomas in NF2 and neurofibromas in NF1.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>NF2 is not associated with the cognitive impairment that is often seen with NF1.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>NF2 is associated with a very high prevalence of bilateral acoustic schwannomas.</p><p/><p class=\"headingAnchor\" id=\"H21346457\"><span class=\"h2\">Noonan syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Noonan syndrome is characterized principally by short stature, webbed neck, characteristic facial features (hypertelorism, downward eye slant, and low-set ears), and pulmonic stenosis [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/145\" class=\"abstract_t\">145</a>]. Affected individuals may have caf&eacute;-au-lait spots, sometimes more than six that are larger than 5 mm, which fulfills a diagnostic criterion for NF1 in children. In addition, the facial features of Noonan syndrome are sometimes also seen in individuals with NF1. Noonan syndrome is due to mutation in one of several genes in the Ras signaling pathway, especially <em>PTPN11</em> (protein-tyrosine phosphatase, nonreceptor-type, 11)<em>. </em>(See <a href=\"topic.htm?path=causes-of-short-stature#H19\" class=\"medical medical_review\">&quot;Causes of short stature&quot;, section on 'Noonan syndrome'</a> and <a href=\"topic.htm?path=valvar-subvalvar-and-supravalvar-pulmonic-stenosis-ps-and-peripheral-pulmonic-stenosis-pps-in-children-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Valvar, subvalvar, and supravalvar pulmonic stenosis (PS) and peripheral pulmonic stenosis (PPS) in children: Clinical manifestations and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topic (see <a href=\"topic.htm?path=neurofibromatosis-type-1-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Neurofibromatosis type 1 (The Basics)&quot;</a>)</p><p/><p>Information for patients about NF1 is available online through the <a href=\"http://www.ctf.org/&amp;token=+jthRkjdsLnFA9mGZDkS4gyMvaJND3DZjnCTtwxGIr0=&amp;TOPIC_ID=2939\" target=\"_blank\" class=\"external\">Children's Tumor Foundation</a>.</p><p class=\"headingAnchor\" id=\"H10683464\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There are three major clinically and genetically distinct forms of neurofibromatosis, neurofibromatosis types 1 and 2 (NF1 and NF2) and schwannomatosis. NF1, also known as von Recklinghausen disease, is the most common type. The hallmarks of NF1 are the multiple caf&eacute;-au-lait macules and associated cutaneous neurofibromas (<a href=\"image.htm?imageKey=PEDS%2F69606\" class=\"graphic graphic_picture graphicRef69606 \">picture 2</a>). The condition is called segmental NF1 when clinical features are limited to one area of the body. (See <a href=\"#H20885983\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>NF1 is an autosomal dominant disorder caused by mutations in the <em>NF1</em> gene that encodes the protein neurofibromin. Penetrance is complete, but expression is highly variable. Segmental NF1 is caused by somatic mosaicism due to a postzygotic mutation in the <em>NF1</em> gene. (See <a href=\"#H20885999\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The typical order of appearance of clinical manifestations is caf&eacute;-au-lait macules, axillary <span class=\"nowrap\">and/or</span> inguinal freckling, Lisch nodules (iris hamartomas), and neurofibromas. Osseous lesions, if present, usually appear during the patient's first year after birth, and symptomatic optic pathway glioma (OPG) usually occurs by the time the patient is three years of age (<a href=\"image.htm?imageKey=PEDS%2F53064\" class=\"graphic graphic_table graphicRef53064 \">table 1</a>). Other tumors and neurologic complications typically begin to appear after the first year of life, and hypertension and malignant transformation of tumors may occur in adolescence and adulthood. (See <a href=\"#H20886007\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of NF1 is based upon the presence of characteristic clinical features (<a href=\"image.htm?imageKey=PEDS%2F63696\" class=\"graphic graphic_table graphicRef63696 \">table 2</a>). Genetic testing is not required to make the diagnosis but can be helpful in confirming the diagnosis for children who do not meet diagnostic criteria or only demonstrate caf&eacute;-au-lait macules and axillary freckling. Children suspected of having NF1 should be evaluated by a multidisciplinary team that includes pediatric neurology, genetics, and ophthalmology. This team should examine the child for diagnostic criteria and treatable complications and also provide anticipatory guidance. (See <a href=\"#H20886015\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The differential diagnosis of NF1 includes Legius syndrome, constitutional mismatch repair-deficiency (CMMR-D) syndrome, NF2, and Noonan syndrome. (See <a href=\"#H20886023\" class=\"local\">'Differential diagnosis'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H21346386\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge Sharon E Plon, MD, PhD, who contributed to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/1\" class=\"nounderline abstract_t\">Lammert M, Friedman JM, Kluwe L, Mautner VF. Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol 2005; 141:71.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/2\" class=\"nounderline abstract_t\">Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 2010; 152A:327.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/3\" class=\"nounderline abstract_t\">Stephens K, Kayes L, Riccardi VM, et al. Preferential mutation of the neurofibromatosis type 1 gene in paternally derived chromosomes. Hum Genet 1992; 88:279.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/4\" class=\"nounderline abstract_t\">Ruggieri M, Huson SM. The clinical and diagnostic implications of mosaicism in the neurofibromatoses. Neurology 2001; 56:1433.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/5\" class=\"nounderline abstract_t\">Ledbetter DH, Rich DC, O'Connell P, et al. Precise localization of NF1 to 17q11.2 by balanced translocation. Am J Hum Genet 1989; 44:20.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/6\" class=\"nounderline abstract_t\">Feldkamp MM, Gutmann DH, Guha A. Neurofibromatosis type 1: piecing the puzzle together. Can J Neurol Sci 1998; 25:181.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/7\" class=\"nounderline abstract_t\">Shen MH, Harper PS, Upadhyaya M. Molecular genetics of neurofibromatosis type 1 (NF1). J Med Genet 1996; 33:2.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/8\" class=\"nounderline abstract_t\">Martin GA, Viskochil D, Bollag G, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 1990; 63:843.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/9\" class=\"nounderline abstract_t\">Weiss B, Bollag G, Shannon K. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Am J Med Genet 1999; 89:14.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/10\" class=\"nounderline abstract_t\">Gutmann DH, Blakeley JO, Korf BR, Packer RJ. Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opin Investig Drugs 2013; 22:443.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/11\" class=\"nounderline abstract_t\">Easton DF, Ponder MA, Huson SM, Ponder BA. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet 1993; 53:305.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/12\" class=\"nounderline abstract_t\">Stevenson DA, Zhou H, Ashrafi S, et al. Double inactivation of NF1 in tibial pseudarthrosis. Am J Hum Genet 2006; 79:143.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/13\" class=\"nounderline abstract_t\">Maertens O, Brems H, Vandesompele J, et al. Comprehensive NF1 screening on cultured Schwann cells from neurofibromas. Hum Mutat 2006; 27:1030.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/14\" class=\"nounderline abstract_t\">Upadhyaya M, Huson SM, Davies M, et al. An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet 2007; 80:140.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/15\" class=\"nounderline abstract_t\">Pinna V, Lanari V, Daniele P, et al. p.Arg1809Cys substitution in neurofibromin is associated with a distinctive NF1 phenotype without neurofibromas. Eur J Hum Genet 2015; 23:1068.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/16\" class=\"nounderline abstract_t\">Santoro C, Maietta A, Giugliano T, et al. Arg(1809) substitution in neurofibromin: further evidence of a genotype-phenotype correlation in neurofibromatosis type 1. Eur J Hum Genet 2015; 23:1460.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/17\" class=\"nounderline abstract_t\">Korf BR, Henson JW, Stemmer-Rachamimov A. Case records of the Massachusetts General Hospital. Case 13-2005. A 48-year-old man with weakness of the limbs and multiple tumors of spinal nerves. N Engl J Med 2005; 352:1800.</a></li><li class=\"breakAll\">Gutmann DH, Collins FS. Neurofibromatosis 1. In: The metabolic and molecular bases of inherited disease, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.877.</li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/19\" class=\"nounderline abstract_t\">Tonsgard JH, Yelavarthi KK, Cushner S, et al. Do NF1 gene deletions result in a characteristic phenotype? Am J Med Genet 1997; 73:80.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/20\" class=\"nounderline abstract_t\">Leppig KA, Kaplan P, Viskochil D, et al. Familial neurofibromatosis 1 microdeletions: cosegregation with distinct facial phenotype and early onset of cutaneous neurofibromata. Am J Med Genet 1997; 73:197.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/21\" class=\"nounderline abstract_t\">Mensink KA, Ketterling RP, Flynn HC, et al. Connective tissue dysplasia in five new patients with NF1 microdeletions: further expansion of phenotype and review of the literature. J Med Genet 2006; 43:e8.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/22\" class=\"nounderline abstract_t\">Kluwe L, Friedrich RE, Peiper M, et al. Constitutional NF1 mutations in neurofibromatosis 1 patients with malignant peripheral nerve sheath tumors. Hum Mutat 2003; 22:420.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/23\" class=\"nounderline abstract_t\">Upadhyaya M, Spurlock G, Majounie E, et al. The heterogeneous nature of germline mutations in NF1 patients with malignant peripheral serve sheath tumours (MPNSTs). Hum Mutat 2006; 27:716.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/24\" class=\"nounderline abstract_t\">De Raedt T, Beert E, Pasmant E, et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 2014; 514:247.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/25\" class=\"nounderline abstract_t\">Lee W, Teckie S, Wiesner T, et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet 2014; 46:1227.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/26\" class=\"nounderline abstract_t\">Tinschert S, Naumann I, Stegmann E, et al. Segmental neurofibromatosis is caused by somatic mutation of the neurofibromatosis type 1 (NF1) gene. Eur J Hum Genet 2000; 8:455.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/27\" class=\"nounderline abstract_t\">Moss C, Green SH. What is segmental neurofibromatosis? Br J Dermatol 1994; 130:106.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/28\" class=\"nounderline abstract_t\">Trevisson E, Forzan M, Salviati L, Clementi M. Neurofibromatosis type 1 in two siblings due to maternal germline mosaicism. Clin Genet 2014; 85:386.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/29\" class=\"nounderline abstract_t\">Bottillo I, Torrente I, Lanari V, et al. Germline mosaicism in neurofibromatosis type 1 due to a paternally derived multi-exon deletion. Am J Med Genet A 2010; 152A:1467.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/30\" class=\"nounderline abstract_t\">Consoli C, Moss C, Green S, et al. Gonosomal mosaicism for a nonsense mutation (R1947X) in the NF1 gene in segmental neurofibromatosis type 1. J Invest Dermatol 2005; 125:463.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/31\" class=\"nounderline abstract_t\">L&aacute;zaro C, Ravella A, Gaona A, et al. Neurofibromatosis type 1 due to germ-line mosaicism in a clinically normal father. N Engl J Med 1994; 331:1403.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/32\" class=\"nounderline abstract_t\">DeBella K, Szudek J, Friedman JM. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 2000; 105:608.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/33\" class=\"nounderline abstract_t\">Korf BR. Diagnostic outcome in children with multiple caf&eacute; au lait spots. Pediatrics 1992; 90:924.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/34\" class=\"nounderline abstract_t\">Nunley KS, Gao F, Albers AC, et al. Predictive value of caf&eacute; au lait macules at initial consultation in the diagnosis of neurofibromatosis type 1. Arch Dermatol 2009; 145:883.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/35\" class=\"nounderline abstract_t\">Ben-Shachar S, Dubov T, Toledano-Alhadef H, et al. Predicting neurofibromatosis type 1 risk&nbsp;among children with isolated caf&eacute;-au-lait&nbsp;macules. J Am Acad Dermatol 2017; 76:1077.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/36\" class=\"nounderline abstract_t\">Friedman JM, Birch PH. Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet 1997; 70:138.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/37\" class=\"nounderline abstract_t\">Lewis RA, Riccardi VM. Von Recklinghausen neurofibromatosis. Incidence of iris hamartomata. Ophthalmology 1981; 88:348.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/38\" class=\"nounderline abstract_t\">Gutmann DH. Recent insights into neurofibromatosis type 1: clear genetic progress. Arch Neurol 1998; 55:778.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/39\" class=\"nounderline abstract_t\">Seminog OO, Goldacre MJ. Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study. Br J Cancer 2013; 108:193.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/40\" class=\"nounderline abstract_t\">Airewele GE, Sigurdson AJ, Wiley KJ, et al. Neoplasms in neurofibromatosis 1 are related to gender but not to family history of cancer. Genet Epidemiol 2001; 20:75.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/41\" class=\"nounderline abstract_t\">S&oslash;rensen SA, Mulvihill JJ, Nielsen A. Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med 1986; 314:1010.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/42\" class=\"nounderline abstract_t\">Walker L, Thompson D, Easton D, et al. A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer 2006; 95:233.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/43\" class=\"nounderline abstract_t\">Tucker T, Riccardi VM, Sutcliffe M, et al. Different patterns of mast cells distinguish diffuse from encapsulated neurofibromas in patients with neurofibromatosis 1. J Histochem Cytochem 2011; 59:584.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/44\" class=\"nounderline abstract_t\">Sheela S, Riccardi VM, Ratner N. Angiogenic and invasive properties of neurofibroma Schwann cells. J Cell Biol 1990; 111:645.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/45\" class=\"nounderline abstract_t\">Jouhilahti EM, Peltonen S, Callens T, et al. The development of cutaneous neurofibromas. Am J Pathol 2011; 178:500.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/46\" class=\"nounderline abstract_t\">Carroll SL, Ratner N. How does the Schwann cell lineage form tumors in NF1? Glia 2008; 56:1590.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/47\" class=\"nounderline abstract_t\">Dugoff L, Sujansky E. Neurofibromatosis type 1 and pregnancy. Am J Med Genet 1996; 66:7.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/48\" class=\"nounderline abstract_t\">Lott IT, Richardson EP Jr. Neuropathological findings and the biology of neurofibromatosis. Adv Neurol 1981; 29:23.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/49\" class=\"nounderline abstract_t\">Dombi E, Solomon J, Gillespie AJ, et al. NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Neurology 2007; 68:643.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/50\" class=\"nounderline abstract_t\">Plotkin SR, Bredella MA, Cai W, et al. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One 2012; 7:e35711.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/51\" class=\"nounderline abstract_t\">Prada CE, Rangwala FA, Martin LJ, et al. Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1. J Pediatr 2012; 160:461.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/52\" class=\"nounderline abstract_t\">Serletis D, Parkin P, Bouffet E, et al. Massive plexiform neurofibromas in childhood: natural history and management issues. J Neurosurg 2007; 106:363.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/53\" class=\"nounderline abstract_t\">Lewis RA, Gerson LP, Axelson KA, et al. von Recklinghausen neurofibromatosis. II. Incidence of optic gliomata. Ophthalmology 1984; 91:929.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/54\" class=\"nounderline abstract_t\">Gutmann DH, Rasmussen SA, Wolkenstein P, et al. Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neurology 2002; 59:759.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/55\" class=\"nounderline abstract_t\">Listernick R, Ferner RE, Piersall L, et al. Late-onset optic pathway tumors in children with neurofibromatosis 1. Neurology 2004; 63:1944.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/56\" class=\"nounderline abstract_t\">North K. Neurofibromatosis type 1: review of the first 200 patients in an Australian clinic. J Child Neurol 1993; 8:395.</a></li><li class=\"breakAll\">Riccardi VM. Neurofibromatosis: Phenotype, natural history, and pathogenesis, Johns Hopkins University Press, Baltimore 1992.</li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/58\" class=\"nounderline abstract_t\">Listernick R, Charrow J, Gutmann DH. Intracranial gliomas in neurofibromatosis type 1. Am J Med Genet 1999; 89:38.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/59\" class=\"nounderline abstract_t\">Guillamo JS, Cr&eacute;ange A, Kalifa C, et al. Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain 2003; 126:152.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/60\" class=\"nounderline abstract_t\">Listernick R, Charrow J, Greenwald MJ, Esterly NB. Optic gliomas in children with neurofibromatosis type 1. J Pediatr 1989; 114:788.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/61\" class=\"nounderline abstract_t\">Listernick R, Charrow J, Greenwald M, Mets M. Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr 1994; 125:63.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/62\" class=\"nounderline abstract_t\">Thiagalingam S, Flaherty M, Billson F, North K. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology 2004; 111:568.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/63\" class=\"nounderline abstract_t\">Szudek J, Birch P, Friedman JM. Growth in North American white children with neurofibromatosis 1 (NF1). J Med Genet 2000; 37:933.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/64\" class=\"nounderline abstract_t\">Clementi M, Milani S, Mammi I, et al. Neurofibromatosis type 1 growth charts. Am J Med Genet 1999; 87:317.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/65\" class=\"nounderline abstract_t\">Listernick R, Ferner RE, Liu GT, Gutmann DH. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 2007; 61:189.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/66\" class=\"nounderline abstract_t\">Hersh JH, American Academy of Pediatrics Committee on Genetics. Health supervision for children with neurofibromatosis. Pediatrics 2008; 121:633.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/67\" class=\"nounderline abstract_t\">Cr&eacute;ange A, Zeller J, Rostaing-Rigattieri S, et al. Neurological complications of neurofibromatosis type 1 in adulthood. Brain 1999; 122 ( Pt 3):473.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/68\" class=\"nounderline abstract_t\">Friedman JM, Birch P. An association between optic glioma and other tumours of the central nervous system in neurofibromatosis type 1. Neuropediatrics 1997; 28:131.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/69\" class=\"nounderline abstract_t\">Mahdi J, Shah AC, Sato A, et al. A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1. Neurology 2017; 88:1584.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/70\" class=\"nounderline abstract_t\">Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 2002; 62:1573.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/71\" class=\"nounderline abstract_t\">Pannu AK, Sharma N. Neurofibromatosis type 1 and disseminated malignant peripheral nerve sheath tumor. QJM 2017; 110:583.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/72\" class=\"nounderline abstract_t\">Ferner RE, Golding JF, Smith M, et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol 2008; 19:390.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/73\" class=\"nounderline abstract_t\">Ducatman BS, Scheithauer BW, Piepgras DG, et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986; 57:2006.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/74\" class=\"nounderline abstract_t\">Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007; 44:81.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/75\" class=\"nounderline abstract_t\">McGaughran JM, Harris DI, Donnai D, et al. A clinical study of type 1 neurofibromatosis in north west England. J Med Genet 1999; 36:197.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/76\" class=\"nounderline abstract_t\">Z&ouml;ller ME, Rembeck B, Od&eacute;n A, et al. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 1997; 79:2125.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/77\" class=\"nounderline abstract_t\">Meis JM, Enzinger FM, Martz KL, Neal JA. Malignant peripheral nerve sheath tumors (malignant schwannomas) in children. Am J Surg Pathol 1992; 16:694.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/78\" class=\"nounderline abstract_t\">Porter DE, Prasad V, Foster L, et al. Survival in Malignant Peripheral Nerve Sheath Tumours: A Comparison between Sporadic and Neurofibromatosis Type 1-Associated Tumours. Sarcoma 2009; 2009:756395.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/79\" class=\"nounderline abstract_t\">Anghileri M, Miceli R, Fiore M, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer 2006; 107:1065.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/80\" class=\"nounderline abstract_t\">Ferrari A, Bisogno G, Macaluso A, et al. Soft-tissue sarcomas in children and adolescents with neurofibromatosis type 1. Cancer 2007; 109:1406.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/81\" class=\"nounderline abstract_t\">Sung L, Anderson JR, Arndt C, et al. Neurofibromatosis in children with Rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma study IV. J Pediatr 2004; 144:666.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/82\" class=\"nounderline abstract_t\">Southcott R, Lucraft HH. Association of soft tissue sarcomas other than neurofibrosarcoma with neurofibromatosis. Clin Oncol (R Coll Radiol) 2002; 14:431.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/83\" class=\"nounderline abstract_t\">Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 2006; 30:90.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/84\" class=\"nounderline abstract_t\">Takazawa Y, Sakurai S, Sakuma Y, et al. Gastrointestinal stromal tumors of neurofibromatosis type I (von Recklinghausen's disease). Am J Surg Pathol 2005; 29:755.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/85\" class=\"nounderline abstract_t\">Calabuig-Farinas S, Lopez-Guerrero JA, Llombart-Bosch A. The GIST paradigm: how to establish diagnostic and prognostic criteria. Arkh Patol 2011; 73:13.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/86\" class=\"nounderline abstract_t\">Stewart DR, Sloan JL, Yao L, et al. Diagnosis, management, and complications of glomus tumours of the digits in neurofibromatosis type 1. J Med Genet 2010; 47:525.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/87\" class=\"nounderline abstract_t\">Sharif S, Moran A, Huson SM, et al. Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet 2007; 44:481.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/88\" class=\"nounderline abstract_t\">Madanikia SA, Bergner A, Ye X, Blakeley JO. Increased risk of breast cancer in women with NF1. Am J Med Genet A 2012; 158A:3056.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/89\" class=\"nounderline abstract_t\">Wang X, Levin AM, Smolinski SE, et al. Breast cancer and other neoplasms in women with neurofibromatosis type 1: a retrospective review of cases in the Detroit metropolitan area. Am J Med Genet A 2012; 158A:3061.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/90\" class=\"nounderline abstract_t\">Seminog OO, Goldacre MJ. Age-specific risk of breast cancer in women with neurofibromatosis type 1. Br J Cancer 2015; 112:1546.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/91\" class=\"nounderline abstract_t\">Korf BR. Malignancy in neurofibromatosis type 1. Oncologist 2000; 5:477.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/92\" class=\"nounderline abstract_t\">Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997; 278:51.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/93\" class=\"nounderline abstract_t\">Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988; 45:575.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/94\" class=\"nounderline abstract_t\">Brunetti-Pierri N, Doty SB, Hicks J, et al. Generalized metabolic bone disease in Neurofibromatosis type I. Mol Genet Metab 2008; 94:105.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/95\" class=\"nounderline abstract_t\">Delucia TA, Yohay K, Widmann RF. Orthopaedic aspects of neurofibromatosis: update. Curr Opin Pediatr 2011; 23:46.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/96\" class=\"nounderline abstract_t\">Stevenson DA, Birch PH, Friedman JM, et al. Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1. Am J Med Genet 1999; 84:413.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/97\" class=\"nounderline abstract_t\">Stevenson DA, Viskochil DH, Schorry EK, et al. The use of anterolateral bowing of the lower leg in the diagnostic criteria for neurofibromatosis type 1. Genet Med 2007; 9:409.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/98\" class=\"nounderline abstract_t\">Stevenson DA, Little D, Armstrong L, et al. Approaches to treating NF1 tibial pseudarthrosis: consensus from the Children's Tumor Foundation NF1 Bone Abnormalities Consortium. J Pediatr Orthop 2013; 33:269.</a></li><li class=\"breakAll\">Plon SE. The phakomatoses and other neurocutaneous syndromes. In: Oski's pediatrics: Principles and practice, 4th ed, McMillan JA, Feigin RD, DeAngelis C, Jones MD (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p.2379.</li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/100\" class=\"nounderline abstract_t\">Heerv&auml; E, Koffert A, Jokinen E, et al. A controlled register-based study of 460 neurofibromatosis 1 patients: increased fracture risk in children and adults over 41 years of age. J Bone Miner Res 2012; 27:2333.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/101\" class=\"nounderline abstract_t\">Soucy EA, Gao F, Gutmann DH, Dunn CM. Developmental delays in children with neurofibromatosis type 1. J Child Neurol 2012; 27:641.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/102\" class=\"nounderline abstract_t\">North K. Neurofibromatosis type 1. Am J Med Genet 2000; 97:119.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/103\" class=\"nounderline abstract_t\">Lorenzo J, Barton B, Arnold SS, North KN. Developmental trajectories of young children with neurofibromatosis type 1: a longitudinal study from 21 to 40 months of age. J Pediatr 2015; 166:1006.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/104\" class=\"nounderline abstract_t\">Plasschaert E, Descheemaeker MJ, Van Eylen L, et al. Prevalence of Autism Spectrum Disorder symptoms in children with neurofibromatosis type 1. Am J Med Genet B Neuropsychiatr Genet 2015; 168B:72.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/105\" class=\"nounderline abstract_t\">Hyman SL, Shores A, North KN. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 2005; 65:1037.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/106\" class=\"nounderline abstract_t\">North KN, Riccardi V, Samango-Sprouse C, et al. Cognitive function and academic performance in neurofibromatosis. 1: consensus statement from the NF1 Cognitive Disorders Task Force. Neurology 1997; 48:1121.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/107\" class=\"nounderline abstract_t\">Cutting LE, Koth CW, Denckla MB. How children with neurofibromatosis type 1 differ from &quot;typical&quot; learning disabled clinic attenders: nonverbal learning disabilities revisited. Dev Neuropsychol 2000; 17:29.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/108\" class=\"nounderline abstract_t\">Galasso C, Lo-Castro A, Di Carlo L, et al. Planning deficit in children with neurofibromatosis type 1: a neurocognitive trait independent from attention-deficit hyperactivity disorder (ADHD)? J Child Neurol 2014; 29:1320.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/109\" class=\"nounderline abstract_t\">Kulkantrakorn K, Geller TJ. Seizures in neurofibromatosis 1. Pediatr Neurol 1998; 19:347.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/110\" class=\"nounderline abstract_t\">Hsieh HY, Fung HC, Wang CJ, et al. Epileptic seizures in neurofibromatosis type 1 are related to intracranial tumors but not to neurofibromatosis bright objects. Seizure 2011; 20:606.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/111\" class=\"nounderline abstract_t\">Ostendorf AP, Gutmann DH, Weisenberg JL. Epilepsy in individuals with neurofibromatosis type 1. Epilepsia 2013; 54:1810.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/112\" class=\"nounderline abstract_t\">Steen RG, Taylor JS, Langston JW, et al. Prospective evaluation of the brain in asymptomatic children with neurofibromatosis type 1: relationship of macrocephaly to T1 relaxation changes and structural brain abnormalities. AJNR Am J Neuroradiol 2001; 22:810.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/113\" class=\"nounderline abstract_t\">Sperfeld AD, Hein C, Schr&ouml;der JM, et al. Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2. Brain 2002; 125:996.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/114\" class=\"nounderline abstract_t\">Drouet A, Wolkenstein P, Lefaucheur JP, et al. Neurofibromatosis 1-associated neuropathies: a reappraisal. Brain 2004; 127:1993.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/115\" class=\"nounderline abstract_t\">Ferner RE, Hughes RA, Hall SM, et al. Neurofibromatous neuropathy in neurofibromatosis 1 (NF1). J Med Genet 2004; 41:837.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/116\" class=\"nounderline abstract_t\">Fossali E, Signorini E, Intermite RC, et al. Renovascular disease and hypertension in children with neurofibromatosis. Pediatr Nephrol 2000; 14:806.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/117\" class=\"nounderline abstract_t\">Nelson DB, Greer L, Wendel G. Neurofibromatosis and pregnancy: a report of maternal cardiopulmonary compromise. Obstet Gynecol 2010; 116 Suppl 2:507.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/118\" class=\"nounderline abstract_t\">Shimizu K, Okita R, Uchida Y, Hihara J. Long survival after resection for lung metastasis of malignant peripheral nerve sheath tumor in neurofibromatosis 1. Ann Thorac Cardiovasc Surg 2008; 14:322.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/119\" class=\"nounderline abstract_t\">Kitamura M, Wada N, Nagata S, et al. Malignant peripheral nerve sheath tumor associated with neurofibromatosis type 1, with metastasis to the heart: a case report. Diagn Pathol 2010; 5:2.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/120\" class=\"nounderline abstract_t\">Gumbiene L, Petrulioniene Z, Rucinskas K, et al. Pulmonary hypertension: a fatal complication of neurofibromatosis type 1. Respir Care 2011; 56:1844.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/121\" class=\"nounderline abstract_t\">Montani D, Coulet F, Girerd B, et al. Pulmonary hypertension in patients with neurofibromatosis type I. Medicine (Baltimore) 2011; 90:201.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/122\" class=\"nounderline abstract_t\">Carrascosa MF, Larroque IC, Rivero JL, et al. Pulmonary arterial hypertension associated with neurofibromatosis type 1. BMJ Case Rep 2010; 2010.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/123\" class=\"nounderline abstract_t\">Ben-Shachar S, Constantini S, Hallevi H, et al. Increased rate of missense/in-frame mutations in individuals with NF1-related pulmonary stenosis: a novel genotype-phenotype correlation. Eur J Hum Genet 2013; 21:535.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/124\" class=\"nounderline abstract_t\">Shino MY, Rabbani S, Belperio JA, et al. Neurofibromatosis-associated diffuse lung disease: case report. Semin Respir Crit Care Med 2012; 33:572.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/125\" class=\"nounderline abstract_t\">Nardecchia E, Perfetti L, Castiglioni M, et al. Bullous lung disease and neurofibromatosis type-1. Monaldi Arch Chest Dis 2012; 77:105.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/126\" class=\"nounderline abstract_t\">Vlenterie M, Flucke U, Hofbauer LC, et al. Pheochromocytoma and gastrointestinal stromal tumors in patients with neurofibromatosis type I. Am J Med 2013; 126:174.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/127\" class=\"nounderline abstract_t\">Boulkina LS, Newton CA, Drake AJ 3rd, Tanenberg RJ. Acute myocardial infarction attributable to adrenergic crises in a patient with pheochromocytoma and neurofibromatosis 1. Endocr Pract 2007; 13:269.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/128\" class=\"nounderline abstract_t\">Lie JT. Vasculopathies of Neurofibromatosis Type 1 (von Recklinghausen Disease). Cardiovasc Pathol 1998; 7:97.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/129\" class=\"nounderline abstract_t\">Listernick R, Mancini AJ, Charrow J. Segmental neurofibromatosis in childhood. Am J Med Genet A 2003; 121A:132.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/130\" class=\"nounderline abstract_t\">Payne JM, Moharir MD, Webster R, North KN. Brain structure and function in neurofibromatosis type 1: current concepts and future directions. J Neurol Neurosurg Psychiatry 2010; 81:304.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/131\" class=\"nounderline abstract_t\">DiPaolo DP, Zimmerman RA, Rorke LB, et al. Neurofibromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain. Radiology 1995; 195:721.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/132\" class=\"nounderline abstract_t\">Rosenbaum T, Engelbrecht V, Kr&ouml;lls W, et al. MRI abnormalities in neurofibromatosis type 1 (NF1): a study of men and mice. Brain Dev 1999; 21:268.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/133\" class=\"nounderline abstract_t\">Van Es S, North KN, McHugh K, De Silva M. MRI findings in children with neurofibromatosis type 1: a prospective study. Pediatr Radiol 1996; 26:478.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/134\" class=\"nounderline abstract_t\">North K, Joy P, Yuille D, et al. Specific learning disability in children with neurofibromatosis type 1: significance of MRI abnormalities. Neurology 1994; 44:878.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/135\" class=\"nounderline abstract_t\">Denckla MB, Hofman K, Mazzocco MM, et al. Relationship between T2-weighted hyperintensities (unidentified bright objects) and lower IQs in children with neurofibromatosis-1. Am J Med Genet 1996; 67:98.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/136\" class=\"nounderline abstract_t\">Moore BD 3rd, Slopis JM, Jackson EF, et al. Brain volume in children with neurofibromatosis type 1: relation to neuropsychological status. Neurology 2000; 54:914.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/137\" class=\"nounderline abstract_t\">Cutting LE, Koth CW, Burnette CP, et al. Relationship of cognitive functioning, whole brain volumes, and T2-weighted hyperintensities in neurofibromatosis-1. J Child Neurol 2000; 15:157.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/138\" class=\"nounderline abstract_t\">Rea D, Brandsema JF, Armstrong D, et al. Cerebral arteriopathy in children with neurofibromatosis type 1. Pediatrics 2009; 124:e476.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/139\" class=\"nounderline abstract_t\">Cairns AG, North KN. Cerebrovascular dysplasia in neurofibromatosis type 1. J Neurol Neurosurg Psychiatry 2008; 79:1165.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/140\" class=\"nounderline abstract_t\">Rosser TL, Vezina G, Packer RJ. Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1. Neurology 2005; 64:553.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/141\" class=\"nounderline abstract_t\">Messiaen LM, Callens T, Mortier G, et al. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 2000; 15:541.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/142\" class=\"nounderline abstract_t\">Brems H, Chmara M, Sahbatou M, et al. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet 2007; 39:1120.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/143\" class=\"nounderline abstract_t\">Pasmant E, Sabbagh A, Hanna N, et al. SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype. J Med Genet 2009; 46:425.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/144\" class=\"nounderline abstract_t\">Wimmer K, Etzler J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet 2008; 124:105.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/145\" class=\"nounderline abstract_t\">Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. Lancet 2013; 381:333.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/146\" class=\"nounderline abstract_t\">Spits C, De Rycke M, Van Ranst N, et al. Preimplantation genetic diagnosis for neurofibromatosis type 1. Mol Hum Reprod 2005; 11:381.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/147\" class=\"nounderline abstract_t\">Messiaen L, Yao S, Brems H, et al. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. JAMA 2009; 302:2111.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/148\" class=\"nounderline abstract_t\">Kratz CP, Holter S, Etzler J, et al. Rhabdomyosarcoma in patients with constitutional mismatch-repair-deficiency syndrome. J Med Genet 2009; 46:418.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis/abstract/149\" class=\"nounderline abstract_t\">Yeung JT, Pollack IF, Shah S, et al. Optic pathway glioma as part of a constitutional mismatch-repair deficiency syndrome in a patient meeting the criteria for neurofibromatosis type 1. Pediatr Blood Cancer 2013; 60:137.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2939 Version 33.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H10683464\"><span>SUMMARY</span></a></li><li><a href=\"#H20885983\" id=\"outline-link-H20885983\">INTRODUCTION</a></li><li><a href=\"#H20885991\" id=\"outline-link-H20885991\">EPIDEMIOLOGY</a></li><li><a href=\"#H20885999\" id=\"outline-link-H20885999\">PATHOGENESIS</a></li><li><a href=\"#H20886007\" id=\"outline-link-H20886007\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H19620235\" id=\"outline-link-H19620235\">Caf&eacute;-au-lait macules</a></li><li><a href=\"#H19620716\" id=\"outline-link-H19620716\">Freckling</a></li><li><a href=\"#H19621894\" id=\"outline-link-H19621894\">Lisch nodules</a></li><li><a href=\"#H1814439\" id=\"outline-link-H1814439\">Tumors</a><ul><li><a href=\"#H19620723\" id=\"outline-link-H19620723\">- Peripheral neurofibromas</a><ul><li><a href=\"#H19620730\" id=\"outline-link-H19620730\">Cutaneous</a></li><li><a href=\"#H16375435\" id=\"outline-link-H16375435\">Plexiform</a></li><li><a href=\"#H19620744\" id=\"outline-link-H19620744\">Nodular</a></li></ul></li><li><a href=\"#H1815198\" id=\"outline-link-H1815198\">- Optic pathway gliomas</a><ul><li><a href=\"#H2690166103\" id=\"outline-link-H2690166103\">Premature or delayed puberty due to OPGs</a></li></ul></li><li><a href=\"#H1815234\" id=\"outline-link-H1815234\">- Other central nervous system neoplasms</a></li><li><a href=\"#H1815266\" id=\"outline-link-H1815266\">- Soft tissue sarcomas</a><ul><li><a href=\"#H16376385\" id=\"outline-link-H16376385\">Malignant peripheral nerve sheath tumors</a></li><li><a href=\"#H16376392\" id=\"outline-link-H16376392\">Rhabdomyosarcoma</a></li><li><a href=\"#H16376399\" id=\"outline-link-H16376399\">Gastrointestinal stromal tumors</a></li><li><a href=\"#H21346439\" id=\"outline-link-H21346439\">Glomus tumors</a></li></ul></li><li><a href=\"#H1815318\" id=\"outline-link-H1815318\">- Other tumors</a></li></ul></li><li><a href=\"#H19620765\" id=\"outline-link-H19620765\">Bone abnormalities</a><ul><li><a href=\"#H19620772\" id=\"outline-link-H19620772\">- Long bone dysplasia and pseudoarthrosis</a></li><li><a href=\"#H19620779\" id=\"outline-link-H19620779\">- Other bone lesions</a></li><li><a href=\"#H19620786\" id=\"outline-link-H19620786\">- Short stature</a></li><li><a href=\"#H19620793\" id=\"outline-link-H19620793\">- Scoliosis</a></li><li><a href=\"#H19620800\" id=\"outline-link-H19620800\">- Osteoporosis</a></li></ul></li><li><a href=\"#H1812090\" id=\"outline-link-H1812090\">Neurologic abnormalities</a><ul><li><a href=\"#H1812097\" id=\"outline-link-H1812097\">- Cognitive deficits and learning disabilities</a></li><li><a href=\"#H1812111\" id=\"outline-link-H1812111\">- Seizures</a></li><li><a href=\"#H1812118\" id=\"outline-link-H1812118\">- Macrocephaly</a></li><li><a href=\"#H1812125\" id=\"outline-link-H1812125\">- Peripheral neuropathy</a></li></ul></li><li><a href=\"#H1817071\" id=\"outline-link-H1817071\">Hypertension</a></li><li><a href=\"#H13147715\" id=\"outline-link-H13147715\">Other manifestations</a></li><li><a href=\"#H1817163\" id=\"outline-link-H1817163\">Segmental NF1</a></li></ul></li><li><a href=\"#H1810690\" id=\"outline-link-H1810690\">NEUROIMAGING FINDINGS</a><ul><li><a href=\"#H1810697\" id=\"outline-link-H1810697\">NF-associated bright spots</a></li><li><a href=\"#H1810704\" id=\"outline-link-H1810704\">Increased brain volume (megalencephaly)</a></li><li><a href=\"#H1810726\" id=\"outline-link-H1810726\">Cerebrovascular dysplasia</a></li></ul></li><li><a href=\"#H20886015\" id=\"outline-link-H20886015\">DIAGNOSIS</a><ul><li><a href=\"#H20886927\" id=\"outline-link-H20886927\">Diagnostic criteria</a></li><li><a href=\"#H20886947\" id=\"outline-link-H20886947\">Genetic testing</a></li><li><a href=\"#H13148115\" id=\"outline-link-H13148115\">Screening family members</a></li><li><a href=\"#H19621752\" id=\"outline-link-H19621752\">Prenatal testing</a></li></ul></li><li><a href=\"#H20886023\" id=\"outline-link-H20886023\">DIFFERENTIAL DIAGNOSIS</a><ul><li><a href=\"#H20887086\" id=\"outline-link-H20887086\">Legius syndrome</a></li><li><a href=\"#H10683318\" id=\"outline-link-H10683318\">Constitutional mismatch repair-deficiency syndrome</a></li><li><a href=\"#H10683326\" id=\"outline-link-H10683326\">Neurofibromatosis type 2</a></li><li><a href=\"#H21346457\" id=\"outline-link-H21346457\">Noonan syndrome</a></li></ul></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H15410912\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H10683464\" id=\"outline-link-H10683464\">SUMMARY</a></li><li><a href=\"#H21346386\" id=\"outline-link-H21346386\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ALLRG/2939|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=RADIOL/100713\" class=\"graphic graphic_diagnosticimage\">- MRI of optic pathway glioma</a></li></ul></li><li><div id=\"ALLRG/2939|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ALLRG/96125\" class=\"graphic graphic_picture\">- Multiple cafe-au-lait spots in a patient with NF1</a></li><li><a href=\"image.htm?imageKey=PEDS/69606\" class=\"graphic graphic_picture\">- Neurofibromata and cafe-au-lait macules</a></li><li><a href=\"image.htm?imageKey=ALLRG/96124\" class=\"graphic graphic_picture\">- Axillary freckling in a patient with NF1</a></li><li><a href=\"image.htm?imageKey=PEDS/74414\" class=\"graphic graphic_picture\">- Lisch nodules</a></li><li><a href=\"image.htm?imageKey=ALLRG/55032\" class=\"graphic graphic_picture\">- Plexiform neurofibroma in a child with NF1</a></li><li><a href=\"image.htm?imageKey=ALLRG/96127\" class=\"graphic graphic_picture\">- Multiple cutaneous neurofibromas in a patient with NF1</a></li><li><a href=\"image.htm?imageKey=DERM/82613\" class=\"graphic graphic_picture\">- Multiple neurofibromas</a></li><li><a href=\"image.htm?imageKey=ALLRG/96123\" class=\"graphic graphic_picture\">- Plexiform neurofibroma with tissue hypertrophy in NF1</a></li></ul></li><li><div id=\"ALLRG/2939|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/53064\" class=\"graphic graphic_table\">- Features of NF1 by age</a></li><li><a href=\"image.htm?imageKey=PEDS/63696\" class=\"graphic graphic_table\">- Diagnostic criteria NF1</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=adolescent-idiopathic-scoliosis-clinical-features-evaluation-and-diagnosis\" class=\"medical medical_review\">Adolescent idiopathic scoliosis: Clinical features, evaluation, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=attention-deficit-hyperactivity-disorder-in-children-and-adolescents-clinical-features-and-diagnosis\" class=\"medical medical_review\">Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=benign-pigmented-skin-lesions-other-than-melanocytic-nevi-moles\" class=\"medical medical_review\">Benign pigmented skin lesions other than melanocytic nevi (moles)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=causes-of-short-stature\" class=\"medical medical_review\">Causes of short stature</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-chronic-myeloid-leukemia\" class=\"medical medical_review\">Clinical manifestations and diagnosis of chronic myeloid leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=definition-and-diagnosis-of-hypertension-in-children-and-adolescents\" class=\"medical medical_review\">Definition and diagnosis of hypertension in children and adolescents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=definition-etiology-and-evaluation-of-precocious-puberty\" class=\"medical medical_review\">Definition, etiology, and evaluation of precocious puberty</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnostic-approach-to-children-and-adolescents-with-short-stature\" class=\"medical medical_review\">Diagnostic approach to children and adolescents with short stature</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-classification-clinical-presentation-prognostic-features-and-diagnostic-work-up-of-gastrointestinal-stromal-tumors-gist\" class=\"medical medical_review\">Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal stromal tumors (GIST)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fragile-x-syndrome-clinical-features-and-diagnosis-in-children-and-adolescents\" class=\"medical medical_review\">Fragile X syndrome: Clinical features and diagnosis in children and adolescents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lynch-syndrome-hereditary-nonpolyposis-colorectal-cancer-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=moyamoya-disease-etiology-clinical-features-and-diagnosis\" class=\"medical medical_review\">Moyamoya disease: Etiology, clinical features, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neurofibromatosis-type-1-nf1-management-and-prognosis\" class=\"medical medical_review\">Neurofibromatosis type 1 (NF1): Management and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neurofibromatosis-type-2\" class=\"medical medical_review\">Neurofibromatosis type 2</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=office-based-dermatologic-diagnostic-procedures\" class=\"medical medical_review\">Office-based dermatologic diagnostic procedures</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=optic-pathway-glioma\" class=\"medical medical_review\">Optic pathway glioma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-hypertension-in-adults\" class=\"medical medical_review\">Overview of hypertension in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neurofibromatosis-type-1-the-basics\" class=\"medical medical_basics\">Patient education: Neurofibromatosis type 1 (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=peripheral-nerve-tumors\" class=\"medical medical_review\">Peripheral nerve tumors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pheochromocytoma-and-paraganglioma-in-children\" class=\"medical medical_review\">Pheochromocytoma and paraganglioma in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rhabdomyosarcoma-in-childhood-and-adolescence-epidemiology-pathology-and-molecular-pathogenesis\" class=\"medical medical_review\">Rhabdomyosarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=schwannomatosis\" class=\"medical medical_review\">Schwannomatosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=seizures-and-epilepsy-in-children-classification-etiology-and-clinical-features\" class=\"medical medical_review\">Seizures and epilepsy in children: Classification, etiology, and clinical features</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=specific-learning-disabilities-in-children-clinical-features\" class=\"medical medical_review\">Specific learning disabilities in children: Clinical features</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=specific-learning-disabilities-in-children-evaluation\" class=\"medical medical_review\">Specific learning disabilities in children: Evaluation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=valvar-subvalvar-and-supravalvar-pulmonic-stenosis-ps-and-peripheral-pulmonic-stenosis-pps-in-children-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Valvar, subvalvar, and supravalvar pulmonic stenosis (PS) and peripheral pulmonic stenosis (PPS) in children: Clinical manifestations and diagnosis</a></li></ul></div></div>","javascript":null}